SCHEMBL25914348

SCHEMBL25914348

CCOC(=O)Cc1nnc(-c2ccc(Cl)cc2)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.61
SIRT2 Q8IXJ6 1/20 0.50
SIRT1 Q96EB6 1/20 0.50
SIRT3 Q9NTG7 1/20 0.50
HSD17B10 Q99714 4/20 0.46
KDM4E B2RXH2 8/20 0.46
MAPT P10636 7/20 0.46
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
ALDH1A1 P00352 5/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 4/20 0.45
HPGD P15428 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
HTT P42858 2/20 0.45
FPR1 P21462 1/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TSHR P16473 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11983426 0.81 MAPK1 (0.43) RAB9ASIRT2SIRT1SIRT3HSD17B10
SCHEMBL16153996 0.76 RAB9A (1.00) RAB9AHSD17B10KDM4EMAPTMEN1
SCHEMBL12877694 0.75 MAPK1 (0.41) RAB9ASIRT2SIRT1SIRT3HSD17B10
SCHEMBL703931 0.72 MAPT (0.72) RAB9AMAPTKMT2AALDH1A1POLB
SCHEMBL28856012 0.72 HSD17B10 (0.50) RAB9AHSD17B10KDM4EKMT2AALDH1A1
SCHEMBL24987981 0.71 SMN1; SMN2 (0.76) RAB9AHSD17B10KDM4EMAPTMEN1
SCHEMBL24129892 0.70 HSD17B10 (0.41) RAB9AHSD17B10KDM4EKMT2AALDH1A1
SCHEMBL6191819 0.70 KDM4E (0.40) RAB9AHSD17B10KDM4EMAPTMEN1
SCHEMBL24129893 0.70 HSD17B10 (0.56) HSD17B10MAPTALDH1A1POLBLMNA
SCHEMBL8345138 0.69 SIRT2 (0.59) RAB9ASIRT2SIRT1SIRT3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A RAB9A 2204/4885SIRT2 291/4885SIRT1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.